We additionally characterized enzymatic changes in VEGF overexpressing MDA-MB-231 cells, as well as in human prostate cancer PC-3 cells, and in estrogen receptor (ER) positive MCF-7 breast cancer cells engineered to overexpress VEGF. This evidence concerns the gene ESR1 and breast cancer.